secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2025-08-18T23:59:59+00:00
Accession:  0000950170-25-109567
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EMA validates MAA for NewAmsterdam's obicetrapib monotherapy and FDC with ezetimibe
--------------------------------------------------------------------------------

- EMA will review Phase 3 BROADWAY, BROOKLYN and TANDEM trials supporting obicetrapib 10 mg and obicetrapib/ezetimibe FDC.
- NewAmsterdam eligible for up to €863M in milestones and tiered double-digit to mid-twenties % royalties on Menarini territory net sales.
- Obicetrapib monotherapy showed 33-36% LDL-C reduction vs placebo; FDC showed ~50% reduction in TANDEM trial.
- MAA submitted by partner Menarini under exclusive license agreement signed June 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000095017025109567/0000950170-25-109567-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000095017025109567/nams-20250818.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-109567

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer